Background Following an earlier study in which elderly patients with schizophrenia had their typical antipsychotic medication changed to olanzapine or risperidone, the 61 patients were followed for up to a further six months to see if either treatment was superior in terms of efficacy or side effect
The safety of risperidone: a post-marketing study on 7684 patients
β Scribed by F. J. Mackay; L. V. Wilton; G. L. Pearce; S. N. Freemantle; R. D. Mann
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 91 KB
- Volume
- 13
- Category
- Article
- ISSN
- 0885-6222
No coin nor oath required. For personal study only.
β¦ Synopsis
Risperidone is a relatively new antipsychotic agent licensed for the treatment of schizophrenia and other psychotic conditions in patients aged 15 years or older. This study examines the safety of risperidone used in general practice. Information was collected for 7684 patients included in a non-interventional observational cohort study conducted by means of Prescription-Event Monitoring. Incidence rates were calculated to rank the frequency of reported events. Drowsiness/sedation was the most frequent reason for stopping risperidone and the most frequently reported event. Extrapyramidal symptoms were reported rarely, but were more frequent in the elderly. 98 (1 . 3 per cent) patients were aged less than 15 years. Eight overdoses of risperidone alone were reported with no serious clinical sequelae. Risperidone appears to be well tolerated.
π SIMILAR VOLUMES
The aim of this report is to show the results of a pilot, open label treatment programme for resistant schizophrenia in which risperidone was used before clozapine. Thirteen DSM I11 R, drug resistant schizophrenics were treated with risperidone p.0. at doses up to 16 mg/day for three months. Clinica
## Abstract The aim of this study was to compare the effects of olanzapine and risperidone on cognitive functions in patients with schizophrenia. The subjects were schizophrenic outpatients, all meeting DSMβIV diagnostic criteria for schizophrenia and already treated with risperidone. In the experi
A Memory Clinic model set up to diagnose and treat Alzheimer's Disease early in the course of the illness delayed time to institutionalisation by a median of 9 months compared to controls. Treatment included pre and post diagnostic counselling, and psychosocial interventions.
## Abstract The concept of drugβlikeness has been established in the field of drug discovery. Pesticide discovery is also a complicated and rigorous filtering process compared with drug discovery. This study involved investigation of the constitutive properties of 788 marketed pesticides, including